Clinical-stage biopharmaceutical company GRI Bio Inc. (GRI) is under the spotlight ahead of a key clinical milestone, the release of topline data from its fully enrolled Phase 2a trial evaluating GRI-0621 for idiopathic pulmonary fibrosis or IPF. This data, expected in the third quarter of 2025, will offer a more complete picture of the drug's safety, biomarker impact, and potential efficacy over the full 12-week treatment period.
The anticipation follows the release of encouraging interim data from its ongoing Phase 2a clinical trial of GRI-0621.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com